Implications of AD plasma and PET biomarker discordance: Alzheimer disease

Charlotte E. Teunissen; Lisa Vermunt

doi:10.1038/s41582-025-01091-w

Implications of AD plasma and PET biomarker discordance: Alzheimer disease

Charlotte E. Teunissen^*
, Lisa Vermunt

^*Corresponding author for this work

Vrije Universiteit Amsterdam

Research output: Contribution to journal › Comment/Letter to the editor › Academic

50 Downloads (Pure)

Abstract

Plasma biomarker tests for Alzheimer disease are becoming increasingly reliable, which enables implementation in clinical settings in which cerebrospinal fluid analysis and PET scans are unavailable. However, a new study shows that some patients have discordant plasma and PET biomarker results. Clinicians need clear guidance to identify and manage patients who do not fit into standard clinical or biological categories.

Original language	English
Pages (from-to)	295-296
Number of pages	2
Journal	Nature reviews. Neurology
Volume	21
Issue number	6
Early online date	2025
DOIs	https://doi.org/10.1038/s41582-025-01091-w
Publication status	Published - Jun 2025

Access to Document

10.1038/s41582-025-01091-w

Implications-of-ad-plasma-and-pet-biomarker-discordance.pdfFinal published version, 745 KBLicence: Taverne

Cite this

@article{1e83cfaf231b416485fc1e54358ee2da,

title = "Implications of AD plasma and PET biomarker discordance: Alzheimer disease",

abstract = "Plasma biomarker tests for Alzheimer disease are becoming increasingly reliable, which enables implementation in clinical settings in which cerebrospinal fluid analysis and PET scans are unavailable. However, a new study shows that some patients have discordant plasma and PET biomarker results. Clinicians need clear guidance to identify and manage patients who do not fit into standard clinical or biological categories.",

author = "Teunissen, \{Charlotte E.\} and Lisa Vermunt",

note = "Publisher Copyright: {\textcopyright} Springer Nature Limited 2025.",

year = "2025",

month = jun,

doi = "10.1038/s41582-025-01091-w",

language = "English",

volume = "21",

pages = "295--296",

journal = "Nature reviews. Neurology",

issn = "1759-4758",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Implications of AD plasma and PET biomarker discordance

T2 - Alzheimer disease

AU - Teunissen, Charlotte E.

AU - Vermunt, Lisa

PY - 2025/6

Y1 - 2025/6

N2 - Plasma biomarker tests for Alzheimer disease are becoming increasingly reliable, which enables implementation in clinical settings in which cerebrospinal fluid analysis and PET scans are unavailable. However, a new study shows that some patients have discordant plasma and PET biomarker results. Clinicians need clear guidance to identify and manage patients who do not fit into standard clinical or biological categories.

AB - Plasma biomarker tests for Alzheimer disease are becoming increasingly reliable, which enables implementation in clinical settings in which cerebrospinal fluid analysis and PET scans are unavailable. However, a new study shows that some patients have discordant plasma and PET biomarker results. Clinicians need clear guidance to identify and manage patients who do not fit into standard clinical or biological categories.

UR - https://www.scopus.com/pages/publications/105004203814

U2 - 10.1038/s41582-025-01091-w

DO - 10.1038/s41582-025-01091-w

M3 - Comment/Letter to the editor

C2 - 40312572

SN - 1759-4758

VL - 21

SP - 295

EP - 296

JO - Nature reviews. Neurology

JF - Nature reviews. Neurology

IS - 6

ER -

Implications of AD plasma and PET biomarker discordance: Alzheimer disease

Abstract

Access to Document

Other files and links

Fingerprint

Cite this